Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | REN | P00797 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12925072 | 0.80 | HTR6 (0.50) | HTR6ROCK2ROCK1PDE4APDE4B | |
| SCHEMBL24257293 | 0.79 | HTR6 (0.65) | HTR6ROCK2ROCK1PDE4APDE4B | |
| SCHEMBL12898188 | 0.77 | TP53 (0.47) | HTR6ROCK2ROCK1PDE4APDE4B | |
| SCHEMBL12898169 | 0.76 | LMNA (0.50) | HTR6TSHR | |
| SCHEMBL12898175 | 0.76 | HTR6 (0.46) | HTR6ROCK2ROCK1HTR2A | |
| SCHEMBL12898162 | 0.75 | POLB (0.52) | HTR6REN | |
| SCHEMBL12898183 | 0.75 | PIK3C3 (0.47) | HTR6 | |
| SCHEMBL1268405 | 0.75 | HTR6 (0.55) | HTR6ROCK2ROCK1 | |
| SCHEMBL22751959 | 0.74 | HTR6 (0.53) | HTR6ROCK2ROCK1PDE4APDE4B | |
| SCHEMBL12898204 | 0.74 | RAB9A (0.48) | HTR6ROCK2ROCK1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | HTR6 3561/4885ROCK2 793/4885ROCK1 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.